despit
tremend
resourc
invest
prevent
treatment
breast
cancer
remain
lead
caus
cancer
death
women
global
avail
treatment
modal
costli
produc
sever
side
effect
drug
repurpos
relat
new
use
old
drug
emerg
novel
approach
drug
develop
reposit
old
clinic
approv
patent
noncanc
drug
known
target
newer
indic
like
use
old
weapon
new
battl
advanc
genom
proteom
inform
comput
biolog
facilit
process
drug
repurpos
reposit
approach
fasten
process
drug
develop
also
offer
effect
cheaper
safer
drug
lesserknown
side
effect
last
decad
drug
alkyl
agent
anthracyclin
antimetabolit
inhibitor
aromatas
inhibitor
mtor
inhibitor
mitot
inhibitor
reposit
breast
cancer
treatment
reposit
drug
success
use
treatment
aggress
tripl
neg
breast
cancer
literatur
review
suggest
serendip
play
major
role
drug
develop
articl
describ
comprehens
overview
current
scenario
drug
repurpos
breast
cancer
treatment
strategi
well
sever
exampl
repurpos
drug
provid
challeng
associ
drug
repurpos
discuss
unlik
decad
ago
clinician
today
multipl
choic
breast
cancer
treatment
depend
size
stage
grade
metastat
behavior
aggress
intrins
molecular
subtyp
tumor
age
menopaus
statu
overal
health
comorbid
prefer
patient
chemotherapi
hormon
therapi
immunotherapi
radiotherapi
surgeri
common
modal
breast
cancer
primari
choic
treatment
usual
includ
surgeri
aim
complet
resect
major
tumor
mass
first
hand
breast
conserv
lumpectomi
breast
reconstruct
surgeri
mastectomi
lymph
node
dissect
perform
initi
breast
cancer
patient
surgeri
may
preced
system
neoadjuv
therapi
order
shrink
tumor
effect
surgeri
maxim
breast
conserv
exampl
case
trastuzumab
herceptin
pertuzumab
perjeta
breast
cancer
one
common
cancer
women
global
diagnos
physic
examin
breast
scan
tissu
biopsi
total
million
new
case
breast
cancer
identifi
case
die
account
approxim
cancer
death
among
women
global
highest
number
breast
cancer
case
report
asia
follow
europ
north
america
latin
america
caribbean
africa
oceania
although
common
women
breast
cancer
rare
occur
men
vast
heterogen
breast
cancer
molecular
profil
report
base
erpr
express
breast
cancer
type
erpr
ii
er
iii
erpr
iv
aggress
breast
cancer
also
call
tripl
neg
breast
cancer
tnbc
receptor
present
tumor
estim
breast
cancer
hormon
receptor
posit
treat
correspond
therapi
addit
hormon
receptor
biomark
use
clinic
patholog
molecular
character
breast
cancer
includ
cea
etc
molecular
biomark
breast
cancer
use
diagnosi
stage
grade
therapeut
intervent
prognosi
well
clinic
manag
recurr
metastat
case
given
neoadjuv
therapi
trastuzumab
continu
postsurgeri
surgeri
mostli
follow
chemotherapi
radiotherapi
destroy
remnant
micrometastat
cancer
cell
escap
breast
lymph
node
decreas
chanc
recurr
increas
overal
patient
surviv
adjuv
addit
therapi
ie
hormon
target
therapi
provid
breast
cancer
patient
depend
express
hormon
receptor
target
protein
respect
erpr
breast
cancer
patient
given
tamoxifen
aromatas
inhibitor
togeth
altern
surgic
resect
likewis
trastuzumab
herceptin
mostli
recommend
breast
cancer
patient
tnbc
patient
difficult
treat
unfavor
prognosi
gener
administ
standard
chemotherapi
along
parp
inhibitor
dnatarget
platinum
drug
carboplatin
anoth
strategi
base
holist
approach
patient
recoveri
ie
complementari
altern
medicin
holist
approach
patient
advis
sever
life
style
chang
like
exercis
yoga
medit
acupunctur
andor
ayurved
treatment
addit
standard
therapi
unit
state
fda
approv
number
drug
breast
cancer
therapi
tabl
howev
drug
costli
produc
numer
side
effect
common
report
side
effect
patient
includ
fatigu
headach
pain
numb
dental
issu
lymphedema
musculoskelet
symptom
heart
problem
blood
clot
menstrual
menopaus
symptom
infertil
bone
loss
memori
loss
side
effect
hard
toler
patient
alreadi
weaken
diseas
eventu
also
affect
decis
choic
treatment
impair
qualiti
life
necessit
develop
novel
drug
breast
cancer
therapi
previous
review
overal
process
involv
cancer
drug
develop
drug
develop
breast
cancer
like
cancer
type
multistep
process
involv
design
synthesi
character
test
efficaci
toxic
approv
overal
process
lengthi
involv
huge
invest
money
estim
develop
new
drug
usual
requir
year
time
approxim
billion
dollar
top
nearli
drug
fail
clinic
trial
stage
due
unexpect
lack
appropri
efficaci
unaccept
side
effect
regulatori
norm
therefor
approach
expedit
drug
develop
process
requir
one
approach
might
find
new
use
old
clinic
approv
drug
drug
reposit
drug
reposit
aka
drug
repurpos
drug
reprofil
drug
retask
drug
redesign
drug
resort
drug
reindic
indic
switch
therapeut
switch
defin
explor
new
use
old
clinic
approv
drug
reduc
risk
time
cost
drug
reposit
circumv
usual
rout
substanti
higher
rate
slow
pace
side
effect
etc
becom
attract
concept
pharmaceut
industri
estim
reposit
drug
develop
requir
much
lesser
time
year
money
billion
least
known
approv
side
effect
higher
probabl
success
reposit
old
drug
offer
rapid
transit
bench
bedsid
alreadi
approv
fda
regulatori
norm
pass
clinic
trial
approv
human
use
drug
well
defin
pharmacodynam
pharmacokinet
dose
side
effect
metabol
profil
target
molecular
pathway
etc
clinic
develop
directli
start
phase
ii
trial
assess
efficaci
new
indicationdiseas
target
success
exampl
drug
reposit
includ
sildenafil
viagra
thalidomid
viagra
origin
launch
hypertens
angina
pectori
patient
pfizer
howev
patient
develop
penil
erect
side
effect
phase
clinic
trial
drug
later
develop
erectil
dysfunct
total
sale
viagra
billion
dollar
similarli
sed
thalidomid
serendipit
repurpos
erythema
nodosum
leprosum
enl
multipl
myeloma
cancer
recent
advanc
genom
proteom
transcriptom
metabolom
provid
vast
deep
knowledg
molecular
metabol
alter
occur
cancer
fundament
drug
repurpos
integr
system
biolog
bioinformat
depend
basic
concept
ie
activ
base
silico
drug
discoveri
activ
base
drug
repurpos
experiment
approach
drug
candid
evalu
anticanc
activ
directli
drug
structur
similar
would
tend
similar
target
share
biolog
activ
indic
two
diseas
metabol
pathway
signal
affect
drug
target
specif
pathway
use
diseas
irrespect
structur
dissimilar
drug
show
strong
effici
offtarget
side
effect
one
diseas
explor
ie
offtarget
bind
effect
use
novel
indic
drug
diseas
silico
drug
repurpos
approach
base
associ
andor
overlap
diseasegenedrug
paradigm
larg
data
drugdiseas
gene
express
microarray
proteinprotein
interact
geneprotein
interact
signal
pathway
map
signatur
match
genomewid
associ
studi
gwa
use
provid
drugdiseas
gene
associ
network
systemat
integr
coordin
comput
bioinformat
model
dock
structur
model
experiment
statist
machin
learn
etc
variou
data
resourc
avail
use
bioinformat
base
explor
follow
experiment
valid
drug
repurpos
possibl
diseas
similar
gene
express
profil
drug
phenotyp
patient
differ
diseas
map
connect
map
cmap
librari
integr
network
base
cellular
signatur
linc
express
signatur
may
similar
therapeut
applic
import
public
data
resourc
use
networkbas
drug
reposit
includ
gene
set
enrich
analysi
gsea
drugdrug
similar
network
drugbank
onlin
mendelian
inherit
men
omim
geo
predict
drugdiseas
network
kegg
string
biogrid
happi
reactom
pathway
andor
proteinprotein
interact
stitch
druggeneprotein
databas
ttd
therapeut
target
databas
sfinx
drugdrug
interact
sider
drug
side
effect
also
recent
report
drug
repurpos
control
system
theori
decost
comprehens
platform
drug
repurpos
encompass
variou
limit
previou
databas
like
variat
number
copi
gene
interest
mutat
lack
refer
normal
rang
gene
express
etc
differ
diseas
vigor
exploit
networkbas
approach
integr
mention
resourc
identifi
potenti
target
pathway
drug
report
potenti
way
drug
reposit
follow
section
discuss
clinic
approv
drug
origin
use
diseas
breast
cancer
howev
drug
use
explor
breast
cancer
therapi
clinic
approv
reposit
drug
breast
cancer
group
base
mode
action
tabl
drug
divers
term
chemic
structur
fig
abbrevi
cdk
cyclindepend
kinas
erd
er
downregul
lhrh
lutein
hormonereleas
hormon
serd
select
estrogen
receptor
degrad
serm
select
estrogen
receptor
modul
er
estrogen
receptor
pr
progesteron
receptor
human
epiderm
growth
factor
receptor
dna
damag
agent
alkyl
guanin
base
therebi
render
unabl
bind
complementari
strand
lead
inhibit
dna
replic
cancer
cell
growth
alkyl
agent
affect
phase
cell
cycl
cyclophosphamid
known
immunomodul
inhibit
suppress
regulatori
cell
enhanc
effector
cell
tumor
microenviron
show
biphas
effect
ie
low
dose
impart
immunosuppress
function
higher
dose
function
alkyl
agent
lead
death
tumour
well
lymphoid
cell
usual
cyclophosphamid
intraven
iv
administ
breast
cancer
patient
combin
chemotherapeut
docetaxel
paclitaxel
doxorubicin
recommend
regimen
robustli
healthi
breast
cancer
patient
includ
cycl
cyclophosphamid
methotrex
cmf
cycl
adriamycin
cyclophosphamid
ac
thiotepa
deriv
n
n
n
triethylenephosphoramid
tepa
launch
immunosuppress
drug
transplant
hematolog
diseas
subsequ
drug
recommend
solid
tumor
breast
cancer
mgkg
iv
repeat
everi
week
thiotepa
combin
vinblastin
adriamycin
halotestin
vath
effect
patient
relaps
adjuv
therapi
metastat
breast
cancer
patient
anthracyclin
antibiot
intercal
adjac
base
pair
dna
manner
form
anthracyclindnatopoisomeraseii
ternari
complex
ternari
complex
disrupt
reseal
activ
enzym
lead
inhibit
dna
rna
synthesi
highli
replic
cancer
cell
common
anthracyclin
doxorubicin
daunorubicin
epirubicin
idarubicin
gener
extract
streptomyc
bacterium
approv
medic
use
doxorubicin
version
daunorubicin
origin
extract
streptomyc
peucetiu
long
laps
year
first
clinic
usag
anthracyclin
proven
relev
breast
cancer
treatment
howev
establish
chemotherapeut
regimen
contain
doxorubicin
usual
dose
intraven
iv
everi
day
use
regularli
doseintens
dosedens
schedul
regimen
contain
doxorubicin
ac
adriamycin
cyclophosphamid
tac
taxoter
ac
fac
ac
unlik
doxil
pegyl
form
doxorubucin
myocet
nonpegyl
liposom
version
doxorubicin
approv
treatment
metastat
breast
cancer
combin
cyclophosphamid
europ
canada
antimetabolit
chemodrug
interfer
metabol
pathway
cancer
cell
primarili
act
structur
analogu
import
cellular
metabolit
pyrimidin
antimetabolit
uracil
analogu
inhibit
activ
thymidyl
synthetas
convert
fdump
futp
instead
uracil
thymidin
convers
therefor
inhibit
dna
synthesi
cell
also
inhibit
rna
synthesi
due
fdutp
incorpor
rna
lead
highli
toxic
effect
growth
rapidli
multipli
cell
like
cancer
cell
klein
colleagu
introduc
medic
use
treatment
selfheal
squamou
cell
tumor
skin
ie
keratoacanthoma
ka
subsequ
use
cancer
type
includ
breast
cancer
gener
drug
dosag
mgm
mgm
iv
day
day
everi
cycl
six
cycl
total
lokich
et
al
first
introduc
infus
combin
methotrex
breast
cancer
sinc
variou
regim
combin
therapi
contain
f
drug
like
doxorubicin
cisplatin
c
cyclophosphamid
cx
epirubicin
e
ecf
cmf
caf
continu
use
treat
metastat
breast
cancer
combin
paclitaxel
high
dose
doxorubicin
found
success
breast
cancer
treatment
methotrex
folatefol
acid
antagonist
bind
dihydrofol
reductas
dhfr
enzym
inhibit
synthesi
build
block
dna
rna
folic
acid
convert
dihydrofol
dhfr
reduc
tetrahydrofol
thdf
action
thymidin
synthetas
methotrex
bind
dhfr
decreas
synthesi
purin
pyrimidin
cell
inhibit
cell
cycl
progress
sphase
methotrex
discov
substitut
folic
acid
case
decreas
leukem
cell
count
acut
lymphoblast
leukemia
due
dietari
defici
folic
acid
present
clinic
methotrex
first
shown
remit
breast
cancer
jane
c
wright
methotrex
use
singl
cytotox
agent
advanc
breast
cancer
treatment
howev
gianni
bonadonna
group
show
first
treatment
cycl
cmf
combin
mastectomis
women
advanc
cancer
posit
lymph
node
report
treatment
failur
accept
toxic
fact
cmf
regimen
first
ever
schedul
breast
cancer
treatment
cmf
found
equal
effect
even
cycl
immunosuppress
activ
methotrex
explor
clinic
use
autoimmun
diseas
like
rheumatoid
arthriti
gener
dosag
cmf
regimen
defin
cycl
cyclophosphamid
mgm
methotrex
mgm
fluorouracil
mgm
interv
capecitabin
prodrug
anoth
pyrimidin
antimetabolit
convers
capecitabin
requir
three
systemat
enzymat
reaction
cascad
intestin
liver
tumour
cell
enzym
catalyz
last
step
convers
highli
express
tumour
cell
compar
normal
cell
therefor
tumour
select
convers
capecitabin
prevent
system
exposur
bodi
also
capecitabin
easier
administ
safer
better
efficaci
capecitabin
first
use
colon
cancer
capecitabin
given
oral
twice
daili
day
follow
rest
period
cycl
cycl
gener
use
treat
paclitaxel
docetaxel
resist
advanc
metastat
breast
cancer
use
either
alon
combin
cabazitaxel
vinorelbin
ixabepilon
gemcitabin
prodrug
get
triphosphoryl
insid
cell
dfdctp
sequenti
enzym
catalyz
reaction
dfdctp
masquerad
analogu
cytidin
get
incorpor
newli
synthes
dna
gener
irrepar
error
inhibit
dna
replic
lead
cell
death
gemcitabin
primarili
manufactur
larri
hertel
group
eli
lilli
compani
use
antivir
drug
enterovirus
coxsackieviru
drug
also
use
human
rhinovirus
hrv
human
immunodefici
viru
hiv
hepat
c
viru
hcv
polioviru
influenza
viru
zikv
merscov
preclin
test
antitumour
attribut
drug
approv
fda
pancreat
cancer
nonsmal
lung
cancer
final
gemcitabin
approv
metastat
breast
cancer
combin
paclitaxel
anthracyclinecontain
adjuv
chemotherapi
failur
gemcitabin
iv
infus
min
day
cycl
paclitaxel
day
h
infus
gemcitabin
combin
use
firstlin
treatment
metastat
cancer
combin
gemcitabinevinorelbin
gemvin
gemcitabinecisplatin
gemci
gemcitabinecapecitabin
gemcap
also
shown
increas
respons
rate
overal
surviv
pretreat
metastat
breast
cancer
patient
palbociclib
inhibitor
halt
progress
cell
sphase
palbociclib
mg
cycl
aromatas
inhibitor
use
target
therapi
er
advanc
metastat
breast
cancer
conjunct
hormon
therapi
open
label
paloma
palbociclib
ongo
trial
manag
breast
cancer
clinic
trial
design
recent
either
aromatas
inhibitor
letrozol
trial
fulvestr
hormon
therapi
trail
improv
overal
surviv
metastat
breast
cancer
patient
report
phase
iii
clinic
trial
inhibit
activ
delay
resist
hormon
therapi
significantli
improv
progress
free
surviv
pf
patient
hormon
therapi
endocrin
therapi
usual
given
year
therapi
either
directli
target
hormon
estrogen
andor
progesteron
product
neg
regul
function
effect
hormon
sensit
breast
cancer
patient
er
andor
pr
select
estrogen
receptor
modul
serm
serv
antiestrogen
bind
hormon
receptor
antagonist
wide
use
serm
reposit
breast
cancer
drug
tamoxifen
toremifen
raloxifen
tamoxifen
oldest
serm
use
year
earli
stage
breast
cancer
treatment
preand
postmenopaus
women
toremifen
raloxifen
equal
effect
safer
altern
tamoxifen
use
postmenopaus
women
advanc
breast
cancer
multipl
outcom
raloxifen
evalu
clinic
trial
osteoporosi
treatment
trial
postmenopaus
women
secondari
object
evalu
effect
breast
cancer
risk
reduct
lead
design
clinic
trial
continu
outcom
relev
core
raloxifen
use
heart
ruth
studi
tamoxifen
raloxifen
star
aromatas
inhibitor
hormon
therapi
administ
postmenopaus
women
treat
er
earli
andor
late
stage
breast
cancer
act
aromatas
enzym
still
produc
estrogen
hormon
fat
tissu
postmenopaus
women
women
without
activ
ovari
thu
aromatas
inhibitor
reduc
amount
estrogen
postmenopaus
women
breast
cancer
would
otherwis
feed
breast
cancer
cell
growth
aromatas
inhibitor
anastrazol
exemestan
letrozol
initi
use
ovari
stimul
induct
ovul
infertil
femal
polycyst
ovari
syndrom
aromatas
inhibitor
use
neoadjuv
adjuv
therapi
mostli
alon
combin
introduc
altern
tamoxifen
postmenopaus
patient
select
estrogen
receptor
degrad
serd
fulvestr
pure
antiestrogen
block
estrogen
receptor
degrad
receptor
without
agonist
effect
fulvestr
first
use
serd
hormon
therapi
hr
advanc
metastat
breast
cancer
postmenopaus
women
resist
hormon
therapi
use
combin
inhibitor
like
palbociclib
ribociclib
pathway
drug
pictilisib
fergi
buparlisib
lutein
hormon
releas
hormon
lhrh
analog
interfer
signal
mechan
activ
estrogen
synthesi
ovari
caus
temporari
menopaus
goserelin
use
assist
reproduct
prostat
cancer
treatment
goserelin
approv
treatment
premenopaus
women
hormon
sensit
breast
cancer
use
alon
combin
hormon
therapi
goserelin
current
phase
ii
clinic
trial
addit
drug
standard
neoadjuv
therapi
tnbc
patient
goserelin
phase
ii
trial
expect
complet
everolimu
mtor
kinas
inhibitor
inhibit
mtor
signal
pathway
everolimu
origin
approv
renal
cancer
immunosuppress
renal
transplant
pancreat
cancer
phase
iii
clinic
trial
breast
cancer
trial
oral
includ
everolimu
combin
exemestan
success
complet
lead
approv
everolimu
us
fda
treatment
hr
advanc
metastat
cancer
resist
letrozol
anastrazol
mitot
inhibitor
termin
cell
divis
mitosi
disrupt
microtubul
dynam
lead
phase
cell
cycl
arrest
inhibit
spindl
format
common
exampl
mitot
inhibitor
includ
docetaxel
paclitaxel
vinblastin
docetaxel
paclitaxel
induc
cell
cycl
arrest
vinblastin
known
inhibit
spindl
format
docetaxel
paclitaxel
use
neoadjuv
adjuv
therapi
singl
agent
combin
chemotherapeut
agent
treatment
earli
advanc
metastat
breast
cancer
preand
postmenopaus
women
paclitaxel
isol
pacif
yew
use
drug
arteri
restenosi
docetaxel
paclitaxel
initi
use
therapeut
prostat
ovarian
cancer
respect
thereaft
docetaxel
iv
h
doxorubicin
cyclophosphamid
week
x
cycl
paclitaxel
iv
h
week
time
doxorubicincontain
regimen
reposit
chemotherapi
adjunct
breast
cancer
treatment
regimen
taxan
use
part
standard
chemotherapi
metastat
breast
cancer
numer
combinatori
chemotherapi
contain
taxan
use
routin
practic
treat
breast
cancer
clinician
around
globe
vinblastin
natur
occur
vinca
alkaloid
found
white
flower
periwinkl
vinca
rosea
discov
robert
nobl
charl
beer
discoveri
vinblastin
beauti
exampl
serendip
drug
develop
group
rather
aim
evalu
antidiabet
effect
extract
rat
observ
pseudomona
mediat
septicemia
accompani
rapid
wbc
fall
granulocytopenia
studi
direct
show
peripher
granulocytopenia
leukopenia
vinca
rosea
extract
treat
rat
final
report
carcinostat
activ
vinca
rosea
extractvinblastin
rat
transplant
mammari
adenocarcinoma
sarcoma
vinblastin
approv
lymphoma
also
sinc
vinblastin
mgmm
iv
weekli
everi
week
combin
mitomycin
mvp
mitomycin
c
vinblastin
cisplatin
use
chemotherapi
advanc
metastat
breast
cancer
drastic
increas
number
new
case
cost
cancer
treatment
rise
even
higher
speed
diseas
demand
molecular
dissect
gene
protein
level
find
newer
strategi
appropri
target
correspond
drug
requir
lot
time
use
highend
techniqu
pharmaceut
compani
therebi
increas
overal
financi
invest
eventu
cost
drug
antibodybas
immunotherapi
cellbas
cart
therapi
dc
vaccin
act
type
drug
treatment
might
prove
promis
howev
therapi
unafford
patient
develop
well
develop
countri
necessit
develop
drug
higher
efficaci
lower
side
effect
practic
lower
cost
one
smart
way
repurpos
old
exist
approv
drug
newer
indic
advantag
approach
approv
drug
exist
inform
molecular
target
offtarget
mode
action
safeti
level
side
effect
would
save
lot
time
otherwis
requir
discoveri
design
clinic
trial
approv
new
drug
also
reduc
overal
cost
anticanc
drug
cut
cost
involv
preclin
develop
phase
trial
old
drug
would
offpat
henc
cheaper
initi
cost
articl
discuss
detail
advantag
drug
repurpos
breast
cancer
treatment
provid
sever
drug
success
repurpos
breast
cancer
treatment
tripl
neg
breast
cancer
tnbc
highli
heterogen
aggress
complex
form
breast
cancer
without
express
er
pr
receptor
tnbc
untreat
regular
hormon
therapi
howev
combin
chemotherapi
drug
reposit
approach
offer
promis
outcom
preclin
studi
flunarizin
nra
inhibitor
approv
migrain
vertigo
flunarizin
also
shown
promis
tnbc
mous
model
induc
autophagi
recent
public
show
combin
metformin
hemin
use
type
diabet
porphyria
respect
could
inhibit
growth
breast
cancer
cell
bioinformat
tool
reveal
express
significantli
elev
tnbc
hemin
sensit
tnbc
metforminmedi
degrad
complet
repurpos
drug
oncolog
redo
project
provid
evid
new
use
drug
breast
cancer
origin
discov
indic
breast
cancer
drug
includ
mebendazol
antihelminth
cimitedin
antiacid
nitroglycerin
heart
attack
prevent
itraconazol
antifung
diclofenac
antiinflammatori
drug
lnmma
tilarginin
acet
nitric
oxid
synthas
inhibitor
provir
integr
moloney
viru
kinas
pim
inhibitor
olaparib
lasparginas
fenofibr
repurpos
breast
cancer
drug
origin
use
patient
cardiogen
shock
viral
infect
leukemia
helminth
infect
patient
high
serum
cholesterol
triglycerid
respect
implement
network
pharmacolog
examin
potenti
natur
herb
ie
ayurved
formul
tradit
chines
medicin
tcm
also
clinch
attent
research
anticanc
drug
reposit
base
multitarget
synergist
drug
approach
instead
one
targeton
drug
approach
thu
appear
promis
breast
cancer
therapi
integr
supercomput
simul
network
pharmacolog
bioinformat
detect
target
efficaci
herb
triphala
mixtur
least
ayurved
formul
meant
treatment
mani
diseas
bioactivetargetpathwaycanc
type
network
reveal
link
triphala
cancer
type
includ
breast
cancer
bioactiv
target
inform
explor
either
bioactiveor
targetbas
drug
reposit
andor
new
drug
develop
howev
challeng
concern
associ
drug
repurpos
breast
cancer
therapi
requir
thorough
consider
breast
tumor
heterogen
poorli
defin
molecular
signatur
poorli
identifi
drug
dosag
provid
roadblock
drug
repurpos
moreov
current
strategi
often
ignor
tumor
grade
crucial
search
new
therapeut
strategi
certain
stringent
hard
treat
molecular
subgroup
breast
cancer
basal
subtyp
tnbc
mbc
tumor
resist
standard
treatment
therapi
molecular
alter
tnbc
mbc
resist
tumor
type
also
thoroughli
investig
aforement
inhibit
target
energi
gener
mechan
rapidli
grow
cell
inde
novel
approach
otherwis
resistantbreast
cancer
understand
target
tumour
microenviron
instead
tumor
appear
promis
detail
heterogen
breast
cancer
patient
overlap
area
consist
tumour
normal
cell
tumor
microenviron
thoroughli
character
molecular
level
identifi
molecular
basi
superrespond
nonrespond
also
hold
valuabl
insight
deeper
explor
anoth
area
need
attent
strateg
drug
reposit
breast
cancer
person
medicin
ie
extend
reposit
strategi
treat
upto
singl
patient
design
patient
molecular
subgroup
often
present
variat
lead
unexpect
respons
structur
similar
drug
may
time
target
function
dissimilar
protein
henc
pathway
driven
repurpos
strategi
better
multitarget
diseas
like
cancer
orphan
drug
gener
short
patent
thu
repurpos
associ
lower
cost
repurpos
offpat
drug
eventu
block
patent
right
repurpos
drug
henc
futur
investor
inclus
exclus
criteria
select
trial
group
repurpos
drug
crucial
differ
physiolog
respons
anticip
comparison
origin
group
exampl
pregnant
women
first
trimest
cancer
exclud
thalidomid
treatment
due
risk
amelia
phocomelia
drug
compani
expand
reposit
similar
therapeut
area
reus
ovarian
cancer
drug
breast
cancer
drug
success
rate
comparison
success
rate
explor
differ
area
comprehens
largescal
data
mine
research
requir
jump
actual
repurpos
procedur
order
save
time
financ
smallest
error
comput
simul
mislead
entir
studi
faultless
select
relev
pharmacolog
target
use
appropri
databas
tcga
metabr
data
mine
accur
repurpos
strategi
indispens
success
drug
reposit
breast
cancer
repurpos
drug
mainli
includ
phase
iii
clinic
trial
still
challeng
phase
due
longest
durat
huge
invest
inclus
largest
number
patient
compar
phase
phase
ii
clinic
trial
repurpos
drug
breast
cancer
usual
work
monotherapi
polypharmacologycombin
parp
inhibitor
synthet
lethal
mutat
henc
initi
prove
repurpos
drug
efficaci
singl
drug
agent
becom
difficult
toxic
repurpos
drug
pretreat
patient
combin
therapi
unknown
exampl
valproatedoxorubicin
treatment
caus
toxicityinduc
death
two
patient
group
cancer
patient
overal
success
rate
develop
new
drug
reposit
drug
vari
much
ultim
efficaci
remain
also
reposit
drug
anyhow
requir
clinic
reassess
optim
efficaci
cytotox
rout
administr
drug
dosag
differ
older
indic
therebi
increas
overal
cost
reposit
scheme
nonetheless
anim
model
use
drug
test
repres
exact
patient
phenotyp
henc
less
predict
efficaci
real
despit
mani
benefit
drug
reposit
much
attent
requir
lower
drug
dosag
toxic
without
mitig
efficaci
resolv
discuss
limit
cost
effect
effici
drug
develop
articl
comprehens
explain
current
scenario
repurpos
drug
breast
cancer
discuss
detail
need
strategi
drug
reposit
breast
cancer
sever
classic
exampl
drug
reposit
breast
cancer
chemotherapi
futurist
potenti
noncanc
drug
investig
breast
cancer
well
challeng
bottleneck
drug
reposit
also
discuss
thu
conclud
comprehens
approach
select
appropri
geneproteinpathwaytargetdrug
model
via
integr
system
biolog
bioinformat
hold
high
potenti
provid
effici
safer
costeffect
chemotherapeut
treatment
even
stringent
form
breast
cancer
metastat
tripl
neg
scientist
research
clinician
must
continu
work
togeth
extens
present
pharmacolog
databas
multiom
bioinformat
tool
hope
lead
develop
novel
drug
eventu
fight
deadli
breast
cancer
none
